| Press Releases 2011 | |
November 8, 2011 |
|
 |
Cytheris announces interim results from ECLIPSE 2 Hepatitis C multicenter study of IL-7 in chronically infected genotype 1 and 4 nonresponders to standard of care (SOC) |
 |
|
October 26, 2011 |
|
|
Cytheris to Present Interim Data from ECLIPSE 2 Hepatitis C Multicenter Study at AASLD Annual Meeting |
|
|
May 17, 2011 |
|
|
Cytheris and Cancer Immunotherapy Trials Network (CITN) Announce Selection of Recombinant Interleukin-7 (CYT107) for Initial Studies at Member Institutions |
May 11, 2011 |
|
|
Cytheris, Centre Léon Bérard and ImmunID Announce Initiation of Clinical Trial to Evaluate Combination Regimen of IL-7 (CYT107) and XELODA® (capecitabine) in Treatment of Metastatic Breast Cancer |
March 1, 2011 |
|
 |
Cytheris Announces Results of Phase IIa Study Indicating that Recombinant Interleukin-7 (CYT107) Expands CD4 T-Cells in Gut Mucosa of Chronically HIV Infected Immunological Non-Responder Patients |
 |
|
February 22, 2011 |
|
|
Cytheris Announces Publication of Preclinical Study in Cell Showing That Interleukin-7 Engages Multiple Mechanisms To Overcome Chronic Viral Infection and Limit Organ Pathology |
|
|
